Literature DB >> 31173281

LncRNA NKILA inhibits invasion and migration of osteosarcoma cells via NF-κB/Snail signaling pathway.

G-D Zhang1, Y Li, G-J Liao, H-W Qiu.   

Abstract

OBJECTIVE: Our research explored the possible biological function of long non-coding RNA (lncRNA) NKILA in the pathogenesis of osteosarcoma and its underlying mechanism. PATIENTS AND METHODS: NKILA expression in 60 cases of osteosarcoma and adjacent tissues was detected. The correlation between NKILA expression and clinical information was analyzed by Chi-square test. The overexpression plasmid or siRNA of NKILA were transfected into osteosarcoma cells by liposome. Cell proliferation was detected by cell counting kit-8 (CCK-8) assay. Transwell assay was used to check the migratory and invasive abilities. Western Blot was used to detect the expressions of nuclear factor-κB (NF-κB)-related proteins. In addition, we analyzed the cell invasion and migration after treatment of NF-κB inhibitor (JSH) to further verify whether NKILA can participate in the occurrence of osteosarcoma through the NF-κB / Snail signaling pathway.
RESULTS: The expression level of NKILA in osteosarcoma tissues was significantly lower than that in adjacent tissues, and was related to tumor size, Enneking stage, and metastasis. After KNKS/NP cells were transfected with NKILA-siRNA, cell proliferation, invasion and migration were enhanced. Transfection of the NKILA overexpression plasmid in Saos2 cells reduced cell proliferation, invasion and migration. NKILA knockdown downregulated the expressions of p65 and E-cadherin, but strikingly increased Snail expression. The RNA binding protein co-immunoprecipitation experiments illustrated that p65 could bind to NKILA. Additionally, JSH was found to reverse the inhibitory effect of NKILA on cell migration and proliferation.
CONCLUSIONS: NKILA was lowly expressed in osteosarcoma tissues. In addition, high expression of NKILA could suppress the migration and invasion of osteosarcoma cells by inhibiting the NF-κB/Snail signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31173281     DOI: 10.26355/eurrev_201905_17913

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  SNHG15, a p53-regulated lncRNA, suppresses cisplatin-induced apoptosis and ROS accumulation through the miR-335-3p/ZNF32 axis.

Authors:  Yue-Feng Sun; Yuan Wang; Xiao-Dong Li; Hong Wang
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

2.  Curcumol enhances cisplatin sensitivity of gastric cancer: involvement of microRNA-7 and the nuclear factor-kappa B/snail family transcriptional repressor 1 axis.

Authors:  Ying Hu; Ruitong Xu; Jinxia Ma; Zhanpeng Yan; Jun Ma
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Long noncoding RNA NR2F1-AS1 enhances the malignant properties of osteosarcoma by increasing forkhead box A1 expression via sponging of microRNA-483-3p.

Authors:  Shenglong Li; Ke Zheng; Yi Pei; Wei Wang; Xiaojing Zhang
Journal:  Aging (Albany NY)       Date:  2019-12-04       Impact factor: 5.682

Review 4.  Macrophage Long Non-Coding RNAs in Pathogenesis of Cardiovascular Disease.

Authors:  Marcin Wysoczynski; Jae Kim; Joseph B Moore; Shizuka Uchida
Journal:  Noncoding RNA       Date:  2020-07-11

Review 5.  Long noncoding RNAs in osteosarcoma via various signaling pathways.

Authors:  Jinming Han; Xiaohan Shen
Journal:  J Clin Lab Anal       Date:  2020-04-06       Impact factor: 2.352

Review 6.  Expression Level and Clinical Significance of NKILA in Human Cancers: A Systematic Review and Meta-Analysis.

Authors:  Siyuan Tian; Yang Yu; Honghua Huang; Aibing Xu; Hu Xu; Yuan Zhou
Journal:  Biomed Res Int       Date:  2020-08-11       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.